KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Deferred Taxes (2021 - 2025)

Halozyme Therapeutics (HALO) has disclosed Deferred Taxes for 9 consecutive years, with $16.8 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes rose 9.65% to $16.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$634000.0 through Dec 2025, down 19.17% year-over-year, with the annual reading at -$634000.0 for FY2025, 19.17% down from the prior year.
  • Deferred Taxes for Q4 2025 was $16.8 million at Halozyme Therapeutics, up from -$27.4 million in the prior quarter.
  • The five-year high for Deferred Taxes was $142.5 million in Q3 2021, with the low at -$27.4 million in Q3 2025.
  • Average Deferred Taxes over 5 years is $4.4 million, with a median of -$2.6 million recorded in 2023.
  • Peak annual rise in Deferred Taxes hit 321.38% in 2025, while the deepest fall reached 9267.81% in 2025.
  • Over 5 years, Deferred Taxes stood at $13.0 million in 2021, then crashed by 213.3% to -$14.7 million in 2022, then surged by 35.79% to -$9.4 million in 2023, then soared by 262.28% to $15.3 million in 2024, then grew by 9.65% to $16.8 million in 2025.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at $16.8 million, -$27.4 million, and $7.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.